125 related articles for article (PubMed ID: 15928252)
41. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese.
Kamizono S; Hiromatsu Y; Seki N; Bednarczuk T; Matsumoto H; Kimura A; Itoh K
Clin Endocrinol (Oxf); 2000 Jun; 52(6):759-64. PubMed ID: 10848881
[TBL] [Abstract][Full Text] [Related]
42. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy.
Salvi M; Bingoye F; Chung F; Wall JR
J Clin Endocrinol Metab; 1988 May; 66(5):939-45. PubMed ID: 3360902
[TBL] [Abstract][Full Text] [Related]
43. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
44. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema.
Stadlmayr W; Spitzweg C; Bichlmair AM; Heufelder AE
Thyroid; 1997 Feb; 7(1):3-12. PubMed ID: 9086563
[TBL] [Abstract][Full Text] [Related]
45. Regulation of Cyr61/CCN1 gene expression through RhoA GTPase and p38MAPK signaling pathways.
Han JS; Macarak E; Rosenbloom J; Chung KC; Chaqour B
Eur J Biochem; 2003 Aug; 270(16):3408-21. PubMed ID: 12899698
[TBL] [Abstract][Full Text] [Related]
46. Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report.
Rau A; Klopfer M; Rommel N; Rau-Fornefeld M; Kolk A
BMC Ophthalmol; 2018 Feb; 18(1):56. PubMed ID: 29482520
[TBL] [Abstract][Full Text] [Related]
47. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.
Bartalena L; Marcocci C; Chiovato L; Laddaga M; Lepri G; Andreani D; Cavallacci G; Baschieri L; Pinchera A
J Clin Endocrinol Metab; 1983 Jun; 56(6):1139-44. PubMed ID: 6341388
[TBL] [Abstract][Full Text] [Related]
48. Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R
Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
[TBL] [Abstract][Full Text] [Related]
49. Thyrostimulin (a TSH-like Hormone) expression in orbital and thyroid tissue.
Lantz M; Vondrichova T; Capretz A; Nilsson E; Frenander C; Bondeson AG; Ridderstråle M; Aberg M; Asman P; Groop L; Hallengren B
Thyroid; 2007 Feb; 17(2):113-8. PubMed ID: 17316112
[TBL] [Abstract][Full Text] [Related]
50. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy.
Ozata M; Uckaya G; Bolu E; Corapcioglu D; Bingol N; Ozdemir IC
Med Sci Monit; 2001; 7(4):696-700. PubMed ID: 11433197
[TBL] [Abstract][Full Text] [Related]
51. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy.
Aniszewski JP; Valyasevi RW; Bahn RS
J Clin Endocrinol Metab; 2000 Feb; 85(2):776-80. PubMed ID: 10690890
[TBL] [Abstract][Full Text] [Related]
52. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
53. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.
Zhang L; Grennan-Jones F; Lane C; Rees DA; Dayan CM; Ludgate M
J Clin Endocrinol Metab; 2012 Feb; 97(2):653-62. PubMed ID: 22162480
[TBL] [Abstract][Full Text] [Related]
54. Chromosomal mapping and expression of the human cyr61 gene in tumour cells from the nervous system.
Martinerie C; Viegas-Pequignot E; Nguyen VC; Perbal B
Mol Pathol; 1997 Dec; 50(6):310-6. PubMed ID: 9536281
[TBL] [Abstract][Full Text] [Related]
55. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology.
Villanueva R; Inzerillo AM; Tomer Y; Barbesino G; Meltzer M; Concepcion ES; Greenberg DA; MacLaren N; Sun ZS; Zhang DM; Tucci S; Davies TF
Thyroid; 2000 Sep; 10(9):791-8. PubMed ID: 11041456
[TBL] [Abstract][Full Text] [Related]
56. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
57. Cyr61, a deregulated gene in endometriosis.
Absenger Y; Hess-Stumpp H; Kreft B; Krätzschmar J; Haendler B; Schütze N; Regidor PA; Winterhager E
Mol Hum Reprod; 2004 Jun; 10(6):399-407. PubMed ID: 15044605
[TBL] [Abstract][Full Text] [Related]
58. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
60. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
